ClinicalTrials.gg
RecruitingNCT02411773Sym-CKDUpdated May 18, 2026

Sympatholysis in Chronic Kidney Disease

A Phase 1 interventional study of Sodium Bicarbonate and Placebo in Chronic Kidney Disease, sponsored by Emory University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by Emory University · Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jun 2015; still recruiting 11 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies testing Sodium Bicarbonate in Renal Insufficiency, Chronic — 4 open to participants now, 4 under way, none of them phase 3. Sodium Bicarbonate · Renal Insufficiency, Chronic.

Planned enrollment
6th of 19
110 · median 61
Started
2015
with 1 other
Phase 1
4 of 19
1 open now
Registered
9th of 19
by date
Lead sponsor
2 of 19
Emory University

Among the 19 studies testing Sodium Bicarbonate in Renal Insufficiency, Chronic, this one is the 6th largest by planned enrollment, is one of 2 that started in 2015, is one of 4 in phase 1, and was the 9th registered.

Renal Insufficiency, Chronic

3,097 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

4 of the 19 studies testing Sodium Bicarbonate in Renal Insufficiency, Chronic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About Sodium Bicarbonate

Sodium Bicarbonate: first FDA approval 1981 (BSS PLUS). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing Sodium Bicarbonate in Renal Insufficiency, Chronic, or all of them as a file.
02

Study summary

The purpose of this study is to find out why patients with chronic kidney disease (CKD) have poor exercise capacity and what causes an increase in blood pressure during exercise (i.e. increased adrenaline levels, or decreased ability of blood vessels to dilate).

Read the detailed description

Patients with chronic kidney disease (CKD) suffer from exercise intolerance and poor physical capacity which contributes to increased cardiovascular risk in this patient population. Prior studies have shown that CKD patients have an exaggerated increase in blood pressure (BP) during both static and rhythmic exercise. Such abnormal hemodynamic responses to exercise can contribute to poor physical capacity and abnormal muscle blood flow during exercise in these patients. The goals of this project are to investigate the mechanisms and potential therapies targeting the abnormal hemodynamic response during exercise in CKD by examining the roles of impaired vasodilation, and exaggerated vasoconstriction.

03

Conditions studied

  • Chronic Kidney Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Veterans with Stages III and IV Chronic Kidney Disease (CKD)
  • Kidney transplant recipients with varying degrees of kidney function
  • Veterans 18-75 years old, without kidney disease, as study controls
  • Exercise less than 20 minutes twice per week
  • Willing and able to cooperate with the protocol

Exclusion criteria

Exclusion Criteria:

  • Severe CKD (estimated (eGFR) \< 15 cc/minute)
  • Metabolic alkalosis (serum bicarbonate > 28 meq/L)
  • Ongoing drug or alcohol abuse
  • Diabetic neuropathy
  • Any serious systemic disease that might influence survival
  • Severe anemia with (Hbg) level \< 10 g/dL
  • Clinical evidence of congestive heart failure or below 35%
  • Symptomatic heart disease determined by prior , stress test, and/or history
  • Treatment with central alpha agonists (clonidine)
  • Uncontrolled hypertension with blood pressure (BP) greater than 170/100 mmHg
  • Low blood pressure with BP less than 100/50 mmHg
  • Pregnancy or plans to become pregnant
  • Current treatment with monoamine oxidase inhibitors (MAOIs)
  • Inability to exercise on a stationary bicycle
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Active comparator
    Exercise Training plus Sodium Bicarbonate

    Subjects with CKD will undergo exercise training on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. Additionally, subjects will take 1300-2600 mg (2-4 pills) of sodium bicarbonate prior to each exercise session three times a week.

    Drug: Sodium Bicarbonate · Behavioral: Exercise Training

  • Active comparator
    Exercise Training plus Placebo

    Subjects with CKD will undergo exercise training on a stationary bicycle,for 20-45 minutes, 3 times per week, for 6-12 weeks. Additionally, subjects will take 2-4 placebo tablets prior to each exercise session three times a week.

    Drug: Placebo · Behavioral: Exercise Training

  • Active comparator
    Control to Exercise (Stretching) plus Sodium Bicarbonate

    Subjects with CKD will undergo progressive whole body stretching and toning exercises 3 times a week for 20-45 minutes for 6-12 weeks. Additionally, subjects will take 1300-2600 mg (2-4 pills) of sodium bicarbonate prior to each stretching session three times a week.

    Drug: Sodium Bicarbonate · Behavioral: Control to Exercise (Stretching)

  • Placebo comparator
    Control to Exercise (Stretching) plus Placebo

    Subjects with CKD will undergo progressive whole body stretching and toning exercises 3 times a week for 20-45 minutes for 6-12 weeks. Additionally, subjects will take 2-4 placebo tablets prior to each exercise session three times a week.

    Drug: Placebo · Behavioral: Control to Exercise (Stretching)

  • No intervention
    Healthy Control

    Healthy subjects without CKD will not receive any interventions.

Interventions

  • Sodium bicarbonate tablet is 650 mg for one tablet. Oral sodium bicarbonate will be given out as 1300mg-2600mg (2-4 pills) prior to each exercise or stretching session. Serum bicarbonate measurements will be monitored throughout the study (at 2 weeks, then every 2-4 weeks thereafter), and bicarbonate dosages will be adjusted to avoid metabolic alkalosis (serum bicarbonate \> 30).

  • DrugPlacebo

    2-4 placebo pills will be given out prior to each exercise or stretching session.

  • BehavioralExercise Training

    Exercise training consists of riding a stationary bicycle for 20-45 minutes, 3 times per week, supervised by trained exercise specialists, for 6-12 weeks. The exercise program will follow the guidelines provided by the American College of Sports Medicine (ACSM) for optimizing cardiovascular fitness. Exercise intensity will begin at low levels (50 percent of resting heart rate) and increase to no greater than 80 percent of resting heart rate. Exercise time will progress, depending on subject's progress, from 20 minutes per session at first, to a maximum of 45 minutes. Trained staff members will give instructions throughout each exercise session. Before beginning each exercise session, subjects will be instructed on a warm-up focusing on preparing the legs for activity.

  • BehavioralControl to Exercise (Stretching)

    Stretching exercise will consist of muscle stretching and toning for 20-45 minutes, 3 times per week, supervised by trained exercise specialists, for 6-12 weeks. Trained staff members will guide subjects with the stretching exercises, and activities are designed to increase flexibility and range of motion. Before beginning each stretching exercise session, subjects will be instructed to warm-up.

06

What researchers measure

Primary outcomes

  1. Change in muscle oxygenation after exercise/stretching training

    Near-infrared spectroscopy (NIRS) will measure and record tissue oxyhemoglobin, deoxyhemoglobin, and total hemoglobin.

    Time frame: Baseline, Week 12

  2. Change in muscle interstitial pH after exercise/stretching training

    Near-infrared spectroscopy (NIRS) will give an estimation of the pH levels within the muscle interstitial space. Muscle interstitial pH markedly decreases during exercise, and is often lower than blood pH with a larger intracellular to interstitial pH gradient. CKD patients may have less ability to buffer pH changes in the interstitial space during exercise. Bicarbonate supplementation may improve muscle interstitial buffering capacity during exercise, and prevent exaggerated reductions in muscle interstitial pH during exercise.

    Time frame: Baseline, Week 12

  3. Change in venoconstriction after exercise/stretching training

    Dorsal hand vein model will be used to assess vascular alpha-1 adrenergic responsiveness by measuring the degree of venous constriction in response to varying dosages of local phenylephrine (PE) infusion.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Change in Functional Sympatholysis

    Functional sympatholysis is determined by measuring the change in forearm oxygenation via near infrared spectroscopy (NIRS), and forearm blood flow and conductance using ultrasound, during sympathetic activation induced by lower body negative pressure (LBNP), at rest and during handgrip exercise. NIRS measures and records tissue oxyhemoglobin, deoxyhemoglobin, and total hemoglobin.

    Time frame: Baseline, 30 minutes

  2. Change in muscle interstitial pH after handgrip exercise

    Near-infrared spectroscopy (NIRS) will give an estimation of the pH levels within the muscle interstitial space. Muscle interstitial pH markedly decreases during exercise, and is often lower than blood pH with a larger intracellular to interstitial pH gradient. CKD patients may have less ability to buffer pH changes in the interstitial space during exercise. Bicarbonate supplementation may improve muscle interstitial buffering capacity during exercise, and prevent exaggerated reductions in muscle interstitial pH during exercise.

    Time frame: Baseline, 30 minutes

  3. Change in Venoconstriction after Phenylephrine

    Vascular function is measured as venoconstriction after administration of phenylephrine. Dorsal hand vein model will be used to assess vascular alpha-1 adrenergic responsiveness by measuring the degree of venous constriction in response to varying dosages of local phenylephrine (PE) infusion.

    Time frame: Baseline, 30 minutes

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2015 (actual). Primary completion is estimated for Jun 2027, 144 months after the start.

Of 109 phase 1 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's planned 144 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2015
First posted
Apr 8, 2015
StartActual
Jun 11, 2015
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02411773
Lead sponsor
Emory University
Responsible party
Jeanie Park (Associate Professor, Emory University) — Principal investigator
First posted
Apr 8, 2015
Start date
Jun 11, 2015
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
May 18, 2026

Study contacts

Dana DaCosta
Contact
drdacos@emory.edu
404-727-7762
Jeanie Park, MD
Contact
404-321-6111 ext. 207070
Jeanie Park, MD
principal investigator · Emory University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium Bicarbonate

Start the discussion